Stock closed on the high of the week; up a penny. That is a great close considering stock traded down to a low at the 200DMA of .45. Now, the real fun begins.
I stick to my projection of 1 1/2 on good data.
Luck to all Longs. Have a good Weekend.
Gee donk, i thought we were getting along after agreement on your term sheet theory....which proved to be all wrong.
You may not like my posts but they do not contain the factual errors yours seem to do recently. Not knowing that the 10k had trial results clearly stated at the end of April is a small mistake. But, stating as fact that is was not in 10k, leaves you about as credible as teach.
Cheer up donk, soon positive results here wont leave any more need for your worthless conspiracy theories or your other obtuse nonsense.................carry on donk
Donk, if you have a strong feeling about benefits, lets hear it. Why always so cryptic?
Money comes from Koreans either way; JV has assets of dry eye, and terms set out earlier. The canadian rights were never going to go outside the JV.
The analyst at Rodman(Ram Selvaraju) who is today, right in front of data, reiterating buy is well rated in the sector. Tipranks is a paid service that covers 50k sell side analysts and they give him 4 out of 5 stars.
So, he is really putting that rating on the line going into trial results. He also had scln as a buy. History to repeat????
250K coming from Regentree vs G-Tree.?
When did the JV get funded with cash? Did I miss that? How much do they have? I didnt know they had any.
RGRX saying cash came form Regentree must have a purpose for the Koreans, maybe some accounting thing, but cash obviously came from G-tree.
I am still amazed at the obvious outright positive implications of additional money coming to RGRX from the Koreans that will only pay off if trial is successful. Now, if results were a couple months out, i wouldnt put much weight on money, but these results are coming any day and Koreans have more than a good "guess" at what results are. Why waste even another dime to TB4 rights for dry eye if results dont look very positive?
The fact that rgrx isnt a buck now on that PR, is a function of the total lack of following this company and this trial has on Wall st. That will change big time next week and will certainly make Shire take notice.
mia, maybe if that wife of yours got that boot of hers off neck, you might be able to think more clearly. As far as posts that have rewarded readers, i direct you to my strong buys at under 10 cents and at the 45 cent pre breakout level. You can find them yourself; they are there.
You are and always have been a equally worthless poster and human being.
And one last chance for the stupid amoung us, who havent averaged down yet(thats you mia), if gtree strong tonight, buy with both hands tomorrow. Mia, ask your wife first.
And last comment to that great bio investor mia. No sale in front of data exudes confidence. And yet, many CEO's of bio's do it. But not here, and that is the point mia.
Mia, why so grim? I am sorry you cant see the lack of insider selling as a positive. It really doesnt matter. Your comments carry no gravitas here. You have never contributed a thing and your constant name calling gets a little tiring.
What is never talked about, or even considered, is the fact that no insider has sold a single share in the history of this company. The closest anyone has ever come to that is when JJ gifted some shares to his daugther...she has not sold. And Italians may have shifted shares around once the brother died, but retain all.
So, none of them has made a dime from the runnup in share price in '14 when stock was a nickel. Now, i know many retail have taken profits on big run, but for the owners that really count, no monitization. I have been in many biotechs where the insiders have sold some shares in front of trial results. But, not here
The only way any of these larger holders make money is if trial next week is a success. Thats the big bet they are more than wiling to make. As far as track record, Sigma Tau was a big holder of scln and qcor at about these same price levels. How did that work out? And the new investors, the Koreans, are deep pocketed and committed to rgrx and tb4. Follow the money
Little rgrx's drug TB4 meets primary endpoints for signs and symptoms of dry eye and proves superior to much talked about Lifitegrast in terms of visual acuity, tear production, site irritation, and non altered sense of taste.?
Do shorts really want to find out? Nite on bid large and going higher after failed manipulation in share price yesterday,
% Shares Owned
GtreeBNT Co., Ltd. (Won Yang, CEO)
Sigma-Tau and affiliates
Chevy Chase, MD
Allan L. Goldstein
Joseph C. McNay
Sno, rgrx needed money badly, had pressure to file the 10k, JJ needed a quick deal. And, canada is no big deal. You know gtree tried to get the EU, but that is great news we kept that because THAT is where the real failure of a successful eye trial is to rgrx shareholders. That market is bigger and growing faster than china.
This is a win win for gtree and rgrx and is about as great a signal of success you will ever get in front of a just about to be release trial result.
You dont pay for a license expansion if you dont think you have successful results. And this close to release of those results, you know that they know.
Great news also, rgrx KEEPS the EU rights.
Time to add
Near high of the day on decent volume. No confirmation of bad data from the ones running the trial. Yesterday appears to be a weak long taking profits.
There should be news on term sheet or trial very soon. Trial data should not be rushed and should be released to provide max exposure....... if that means another week or 2, so be it
Gtree not doing any real volume. If they had bad results you would see million +.
Whatever the reason for todays selloff, its not poor results. Most likely the derisking from someone with profits, or maybe what donk says; a reset of price with pending finance deal.
Hey donk, i like your term sheet posts, but you are wrong about trial results.
In last 10k it was stated very plainly "We expect to report top line data from DES trial at the end of april 2016.
Now, he may delay that, and that is no big deal, but he did set up expectations.
I have a problem with a lack of transparency. I still believe a short attack, but its standard fair for a company that has had an outlier day to make a public comment to the effect " we no of no news that would account for the trading on our shares today."
Ok brew? Have another one. You are a newbie, so cheer up buddy